Atorolimumab

Atorolimumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	RhD
Identifiers
CAS Number	202833-08-7^N
ATC code	None
ChemSpider	none

^NY (what is this?) (verify)

Atorolimumab is an immunosuppressive drug directed against the Rhesus factor.^[1]

References

↑ WHO Drug Information

Immunosuppressive drugs / Immunosuppressants (L04)

Intracellular
(initiation)

Antimetabolites	purine synthesis inhibitors: Azathioprine Mycophenolic acid pyrimidine synthesis inhibitors: Leflunomide Teriflunomide antifolate: Methotrexate

Macrolides/ other IL-2 inhibitors	FKBP/Cyclophilin/Calcineurin: Tacrolimus Ciclosporin Pimecrolimus Abetimus Gusperimus

IMiDs	Lenalidomide Pomalidomide Thalidomide PDE4 inhibitor: Apremilast

Intracellular
(reception)

IL-1 receptor antagonists	Anakinra

mTOR	Sirolimus Everolimus Ridaforolimus Temsirolimus Umirolimus Zotarolimus

Extracellular

Antibodies

Monoclonal

Serum target (noncellular)	Complement component 5 (Eculizumab) TNF (Adalimumab Afelimomab Certolizumab pegol Golimumab Infliximab Nerelimomab) Interleukin 5 (Mepolizumab) Immunoglobulin E (Omalizumab) Interferon (Faralimomab) IL-6 (Elsilimomab) IL-12 and IL-23 (Lebrikizumab Ustekinumab)

Cellular target	CD3 (Muromonab-CD3 Otelixizumab Teplizumab Visilizumab) CD4 (Clenoliximab Keliximab Zanolimumab) CD11a (Efalizumab) CD18 (Erlizumab) CD20 (Obinutuzumab Rituximab Ocrelizumab Pascolizumab) CD23 (Gomiliximab Lumiliximab) CD40 (Teneliximab Toralizumab) CD62L/L-selectin (Aselizumab) CD80 (Galiximab) CD147/Basigin (Gavilimomab) CD154 (Ruplizumab) BLyS (Belimumab Blisibimod) CTLA-4 (Ipilimumab Tremelimumab) CAT (Bertilimumab Lerdelimumab Metelimumab) Integrin (Natalizumab) Interleukin-6 receptor (Tocilizumab) LFA-1 (Odulimomab) IL-2 receptor/CD25 (Basiliximab Daclizumab Inolimomab) T-lymphocyte (Zolimomab aritox)

Unsorted	Atorolimumab Cedelizumab Fontolizumab Maslimomab Morolimumab Pexelizumab Reslizumab Rovelizumab Siplizumab Talizumab Telimomab aritox Vapaliximab Vepalimomab

Polyclonal

-cept (Fusion)

Monoclonal antibodies for the immune system

Immune system ("-l(i[m])-")

Human ("-limu-")	immunosuppression: Abrilumab Adalimumab Anifrolumab Atorolimumab Belimumab Brodalumab Carlumab Dupilumab Durvalumab Eldelumab Fresolimumab Golimumab Lerdelimumab Lirilumab Mavrilimumab Metelimumab Morolimumab Namilumab Oxelumab§ Placulumab Sarilumab Sifalimumab Tabalumab Ulocuplumab Varlilumab immune activation: Ipilimumab Nivolumab Pembrolizumab Tremelimumab Urelumab other: Bertilimumab Zanolimumab

Mouse ("-limo-")	Afelimomab Elsilimomab Faralimomab Gavilimomab Inolimomab Maslimomab Nerelimomab Odulimomab Telimomab aritox Vepalimomab Zolimomab aritox

Chimeric ("-lixi-")	Basiliximab Clenoliximab Galiximab Gomiliximab Infliximab Keliximab Lumiliximab Priliximab Teneliximab Vapaliximab

Humanized ("-lizu-")	immunosuppressive: Aselizumab Apolizumab Benralizumab^† Cedelizumab Certolizumab pegol Daclizumab Eculizumab Efalizumab Epratuzumab Erlizumab Etrolizumab Fontolizumab Itolizumab Lampalizumab Ligelizumab Lulizumab pegol Mepolizumab Mogamulizumab Natalizumab Ocrelizumab Omalizumab Ozoralizumab Pascolizumab Pateclizumab Pembrolizumab Pexelizumab Pidilizumab PRO 140^† Reslizumab Rontalizumab Rovelizumab Ruplizumab Quilizumab Samalizumab Siplizumab Talizumab Teplizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab Vedolizumab Visilizumab TGN1412^§ non-immunosuppressive: Ibalizumab^†

Chimeric + humanized ("-lixizu-")	Otelixizumab

Interleukin ("-k(i[n])-")

Human ("-kinu-")	Briakinumab Canakinumab Fezakinumab Fletikumab Guselkumab Secukinumab Sirukumab Tralokinumab Ustekinumab

Humanized ("-kizu-", "-kinzu-")	Anrukinzumab Clazakizumab Enokizumab Gevokizumab Ixekizumab Lebrikizumab Olokizumab Perakizumab Tildrakizumab

Inflammatory lesions ("-les-")

Mouse ("-leso-")	Besilesomab Fanolesomab^‡ Lemalesomab Sulesomab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia - version of the Thursday, November 19, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.